Thermo Fisher Scientific (TMO) Cash & Equivalents (2009 - 2026)

Thermo Fisher Scientific has disclosed Cash & Equivalents across 18 years of filings, most recently posting $3.3 billion for Q1 2026.

• Quarterly Cash & Equivalents fell 21.29% year-over-year to $3.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 billion (down 21.29% YoY) and the FY2025 annual result came in at $9.9 billion, up 145.75% from the prior year.
• Cash & Equivalents eased to $3.3 billion in Q1 2026, from $9.9 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $9.9 billion in Q4 2025 and troughed at $1.9 billion in Q3 2022.
• A 5-year average of $4.8 billion and a median of $4.1 billion in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 75.73% — and 2025, when it jumped 145.75%.
• Tracing TMO's Cash & Equivalents over 5 years: stood at $8.5 billion in 2022, then slipped by 5.24% to $8.1 billion in 2023, then plunged by 50.37% to $4.0 billion in 2024, then surged by 145.75% to $9.9 billion in 2025, then tumbled by 66.97% to $3.3 billion in 2026.
• Business Quant data shows TMO's Cash & Equivalents at $3.3 billion in Q1 2026, $9.9 billion in Q4 2025, and $2.0 billion in Q3 2025.